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N-glycosylation controls the function 
of junctional adhesion molecule-A
ABSTRACT Junctional adhesion molecule-A (JAM-A) is an adherens and tight junction pro-
tein expressed by endothelial and epithelial cells. JAM-A serves many roles and contributes 
to barrier function and cell migration and motility, and it also acts as a ligand for the leukocyte 
receptor LFA-1. JAM-A is reported to contain N-glycans, but the extent of this modification 
and its contribution to the protein’s functions are unknown. We show that human JAM-A 
contains a single N-glycan at N185 and that this residue is conserved across multiple mam-
malian species. A glycomutant lacking all N-glycans, N185Q, is able to reach the cell surface 
but exhibits decreased protein half-life compared with the wild- type protein. N-glycosylation 
of JAM-A is required for the protein’s ability to reinforce barrier function and contributes to 
Rap1 activity. We further show that glycosylation of N185 is required for JAM-A–mediated 
reduction of cell migration. Finally, we show that N-glycosylation of JAM-A regulates leuko-
cyte adhesion and LFA-1 binding. These findings identify N-glycosylation as critical for JAM-
A’s many functions.
INTRODUCTION
Junctional adhesion molecule-A (JAM-A) was originally described 
as a platelet receptor (Naik et al., 1995) and later as an adherens and 
tight junction protein (Martin-Padura et al., 1998). JAM-A belongs to 
the immunoglobulin (Ig) superfamily of cell adhesion receptors and 
is characterized by two extracellular N-terminal Ig-like domains, a 
transmembrane domain, and a short C-terminal cytoplasmic tail that 
terminates with a PDZ-binding domain (Severson and Parkos, 2009). 
The first extracellular Ig-like domain regulates cis- and trans-homo-
philic interactions (Severson et al., 2008; Monteiro et al., 2014), and 
the second Ig-like domain serves as a ligand for the leukocyte adhe-
sion receptor LFA-1 (Shaw et al., 2004) and stabilizes the aforemen-
tioned homophilic interactions (Wojcikiewicz et al., 2009). The 
C-terminus of JAM-A interacts with numerous proteins including 
zona occludens-1, AF-6 (Ebnet et al., 2000), Par3 (Ebnet et al., 
2001), and CD9 (Peddibhotla et al., 2013). JAM-A has been impli-
cated in a number of cellular functions, including leukocyte diape-
desis (Martin-Padura et al., 1998; Ostermann et al., 2002; Shaw 
et al., 2004), platelet activation (Naik et al., 1995), angiogenesis 
(Naik and Naik, 2006), and barrier function (Aurrand-Lions et al., 
2001; Laukoetter et al., 2007), and is a receptor for reovirus (Barton 
et al., 2001). The protein has been implicated in a number of pa-
thologies, including vascular diseases (Babinska et al., 2007; Schmitt 
et al., 2014), inflammatory bowel disease (Vetrano and Danese, 
2009), and cancers of the breast (Naik et al., 2008; McSherry et al., 
2011; Murakami et al., 2011), lung (Zhang et al., 2013), and pancreas 
(Fong et al., 2012).
JAM-A, like most immunoglobulin superfamily proteins, is pre-
dicted to carry N-glycans on its extracellular domain. Protein N-gly-
cosylation is an enzyme-driven co/posttranslational modification by 
which a core saccharide is covalently attached to the amide residue 
of asparagine in an N-X-S/T/C motif (where X cannot be P; Stanley 
et al., 2009). Subsequent processing in the endoplasmic reticulum 
and Golgi complex generates an array of N-glycan structures, and 
thus numerous “glycoforms” of any given glycoprotein exist on an 
individual cell (Moremen et al., 2012; Breitling and Aebi, 2013; Scott 
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N-glycosylation regulates JAM-A dimerization 
and protein half-life
In some instances, N-glycosylation is required for protein folding 
and is critical for transport of proteins to the plasma membrane 
(Stanley et al., 2009). We next determined whether the N185Q mu-
tant was able to reach the cell surface. CHO cells expressing wt and 
N185Q were incubated with the cell-impermeable sulfo-NHS-biotin 
tag, which allows for the detection of surface-exposed proteins 
when precipitated against streptavidin. As can be seen in Figure 2A, 
both wt and N185Q JAM-A were labeled with sulfo-NHS-biotin, in-
dicating that N-glycosylation is not required for surface transport. As 
a separate readout, surface JAM-A expression was assessed by flow 
cytometric analysis. Both wt and N185Q were able to reach the cell 
surface in CHO cells, HUVECs, and MDA-MB-231 cells (Supplemen-
tal Figure S1).
JAM-A forms homodimers, which are critical to the protein’s 
function (Severson et al., 2008; Monteiro et al., 2014). Moreover, the 
second Ig-like domain, where N185 resides, has been implicated in 
stabilizing these dimers (Wojcikiewicz et al., 2009). Thus we next de-
termined whether N-glycosylation was important for JAM-A dimer-
ization. As seen in Figure 2B, wt JAM-A dimerized in the presence 
of the cell-impermeable cross-linker BS3, whereas the previously 
described dimerization-deficient mutant, 6163 (Mandell et al., 
2004), showed no evidence of dimerization. In the presence of BS3, 
N185Q was able to form homodimers but at a reduced level com-
pared with wt protein. To confirm this finding, we tested the ability 
of CHO cells expressing EV or wt or N185Q JAM-A to adhere and 
spread on JAM-A/fc, as well as the ability of wt to adhere and spread 
on JAM-A/fc treated with PNGaseF to remove N-glycans. The 
wt protein, but not N185Q, was able to adhere and spread to 
function of adhesion molecules such as E-cadherin (Pinho et al., 
2011; Langer et al., 2012), PECAM-1 (Kitazume et al., 2010), 
VE-cadherin (Geyer et al., 1999), and ICAM-1 (Diamond et al., 1991; 
Scott et al., 2013; He et al., 2014) has been reported. No studies 
examined the extent to which human JAM-A is N-glycosylated or 
whether this modification is important for the protein’s function. In a 
proteome-wide screen of N-glycosylated proteins, it was suggested 
that human JAM-A is N-glycosylated at two positions, N185 and 
N191 (Chen et al., 2009). However, the corresponding sequon at 
N191 is –NPT- and is in conflict with the consensus motif, suggesting 
that this site is unlikely to carry an N-linked oligosaccharide. Intrigu-
ingly, N185 is the site of a somatic mutation in breast cancer re-
ported in the COSMIC database (Forbes et al., 2008).
Our studies were undertaken to determine whether human JAM-
A is N-glycosylated and whether this modification is required for 
JAM-A function. We show that human JAM-A carries a single N-
glycan at N185. This modification is not required for protein expres-
sion or transport to the membrane. However, removal of the N-gly-
can abrogates the effect of JAM-A on barrier function, Rap1 activity, 
and collective and single-cell migration and prevents leukocyte 
binding and interaction with LFA-1. Collectively these data demon-
strate that N-glycosylation is required for JAM-A function.
RESULTS
Human JAM-A contains one N-glycan
It was suggested that JAM-A carries N-glycans (Naik et al., 1995; 
Martin-Padura et al., 1998), but these studies failed to determine 
precisely how many N-glycans are on human JAM-A. It is well es-
tablished that N-glycan site occupancy varies across species (Scott 
and Patel, 2013), so we first wanted to determine how many N-
glycans are on human JAM-A, as well as JAM-A expressed by other 
vertebrates. As can be seen in Figure 1A, multispecies alignment 
demonstrates the potential for an N-glycan in the first Ig-like do-
main of rodent JAM-A that is absent in other vertebrates. A consen-
sus N-glycan sequon –NSS- is found in the second Ig-like domain of 
all species analyzed and corresponds to N185 of human JAM-A. 
There are reports of a potential N-glycan on N191 of human JAM-A 
(Chen et al., 2009), but the corresponding sequon is –NPT-, which 
is in conflict with the consensus motif. Indeed, none of the species 
analyzed expresses a consensus N-glycan motif at the residues cor-
responding to N191 in humans, suggesting that this site is not likely 
to be N-glycosylated. To determine the extent to which human 
JAM-A is N-glycosylated, we cultured human umbilical vein endo-
thelial cells (HUVECs), which are widely reported to express JAM-A 
(Martin-Padura et al., 1998; Naik and Naik, 2006), with or without 
tunicamycin, an inhibitor of N-glycosylation, for 36 h and assessed 
JAM-A expression by Western blot analysis. As seen in Figure 1B, 
tunicamycin treatment resulted in a lower–molecular weight 
(∼4 kDa) form of JAM-A, indicating that the protein contains N-
linked sugars. We next wanted to determine how many N-glycans 
human JAM-A supported and performed site-directed mutagene-
sis of N185 and N191. CHO cells were transfected with empty vec-
tor pCDNA3.1 (EV), wild-type human JAM-A (wt), JAM-A point mu-
tant with asparagine 185 mutated to glutamine (JAM-A N185Q), or 
JAM-A N191Q. As can be seen in Figure 1C, JAM-A N185Q ran at 
a reduced molecular weight as compared with wt JAM-A. This re-
duced molecular weight was identical to wt JAM-A protein pro-
duced in the presence of tunicamycin. On the other hand, the 
N191Q mutant migrated at the same molecular weight as wt JAM-
A, indicating that there is no modification at this residue. These 
data demonstrate that human JAM-A carries a single N-glycan at 
N185.
FIGURE 1: Human JAM-A contains a single N-glycan at N185. 
(A) Multispecies alignment of potential N-glycan sites. N-X-S/T 
consensus motifs are underlined. (B) Western blot analysis of JAM-A 
expression in HUVECs with or without tunicamycin (TM) treatment for 
36 h. (C) Western blot analysis of CHO cells stably transfected with 
empty vector control or vectors expressing wild-type, N185Q, or 
N191Q human JAM-A. Some cells were pretreated with TM for 48 h. 
Data are representative of at least three separate experiments.
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assessed using a real-time cell analyzer 
(RTCA; Wittchen et al., 2011). As can be 
seen in Figure 3B, expression of wt JAM-A 
caused a small but significant increase in cell 
index, an arbitrary index of impedance, 
above both EV and N185Q JAM-A after 18 h, 
indicating an increase in barrier function.
It has been reported that JAM-A medi-
ates barrier function by controlling Rap1 ac-
tivity. We next determined Rap1 activity in 
CHO cells expressing EV or wt or N185Q 
human JAM-A that had been confluent for 
24 h. As seen in Figure 3, C and D, expres-
sion of wt JAM-A significantly increased 
Rap1 activity above EV levels. N185Q JAM-
A increased Rap1 activity compared with EV 
levels but to a lesser extent than wt JAM-A. 
Collectively these data show that N-glyco-
sylation of JAM-A is required for the pro-
tein’s ability to increase barrier function.
N-glycosylation controls JAM-A’s 
effects on cell migration
There are numerous reports that JAM-A ex-
pression controls cell spreading, single-cell 
motility, and collective cell migration, with 
the effects being cell-type specific (Bazzoni 
et al., 2005; Naik and Naik, 2006; McSherry 
et al., 2009; Severson et al., 2009). We first 
determined whether expression of wt or 
N185Q altered cell spreading. As seen in Figure 4, A and B, expres-
sion of wt or N185Q JAM-A had no effect on CHO cell spreading on 
fibronectin as assessed by total cell area or cell index by RTCA. 
Overexpression of wt caused an increase in HUVEC spreading but a 
decrease in MDA-MB-231 cell spreading (Supplemental Figure S3), 
highlighting the cell type–specific effects of the protein.
We next determined whether wt or N185 altered cell motility. 
Expression of wt JAM-A caused a significant decrease in single-cell 
velocity of CHO cells (Figure 4C; Supplemental Videos 1–3), as well 
as of HUVECs and MDA-MB-231 cells (Supplemental Figure S4), as 
compared with EV and N185Q. However, there was no effect on 
persistence of migration (Figure 4D).
Because expression of wt JAM-A reduced single-cell motility and 
this effect was glycosylation dependent, we examined whether a 
similar phenomenon occurred in collective migration of cells. As 
seen in Figure 5, expression of wt JAM-A significantly decreased 
wound closure compared with EV and N185Q. There are reports 
that overexpression of JAM-A increases rates of directed migration 
in HUVEC but only on vitronectin (Naik and Naik, 2006). We next 
determined whether this effect was controlled by N-glycosylation of 
JAM-A. As previously reported, overexpression of wt JAM-A in-
creased the rate of haptotaxis of HUVECs to vitronectin but not fi-
bronectin (Supplemental Figure S5). In contrast, N185Q migrated at 
the same rate as EV control toward both matrix proteins. Taken to-
gether, these data demonstrate that N-glycosylation controls JAM-
A–mediated cell motility and migration. There are reports that JAM-
A regulates β1 integrin (CD29) expression in some lines (McSherry 
et al., 2009; Severson et al., 2009) but not others (Huang et al., 
2006; Cera et al., 2009), which could explain some of the foregoing 
observations. Knockdown or overexpression of JAM-A with siRNA 
did not alter CD29 expression in CHO cells, HUVECs, or MDA-
MB-231 cells (Supplemental Figure S6).
JAM-A/fc (Supplemental Figure S2A) only when N-glycans were 
present on the chimeric protein (Supplemental Figure S2B). Finally, 
junctional accumulation between wt and N185Q was assessed by 
confocal microscopy. Junctional accumulation was seen only in cells 
expressing both wt and N185Q JAM-A (Supplemental Figure S1D). 
Collectively these data demonstrate that N-glycans regulate JAM-A 
homophilic interactions.
Protein dimerization and N-glycans can both increase a protein’s 
half-life by prolonging surface residency through interactions with 
other saccharides on the cell’s surface. To determine whether N-
glycosylation was a regulator of JAM-A half-life, we incubated cells 
with the translation inhibitor cycloheximide and monitored JAM-A 
depletion within whole-cell lysates. As can be seen in Figure 2C, the 
decay of N185Q was significantly increased compared with wt pro-
tein. Collectively these data show that N-glycosylation is not re-
quired for JAM-A transport but is a critical regulator of dimerization 
and protein stability.
N-glycosylation is required for JAM-A’s effects 
on barrier function
Previously it was reported that expression of JAM-A in CHO cells 
reduces paracellular passage of fluorescein isothiocyanate–dextran 
(Martin-Padura et al., 1998; Aurrand-Lions et al., 2001). To deter-
mine whether glycosylation of JAM-A is required to support this 
function, we measured FITC-dextran flux across CHO cell monolay-
ers expressing EV or wt or N185Q JAM-A. As seen in Figure 3A, 
expression of wt JAM-A reduced paracellular leak of FITC-dextran 
compared with EV control. However, N185Q JAM-A demonstrated 
a similar level of flux as EV cells, indicating that the N-glycan residue 
was critical for this increase in barrier function. As a separate readout 
of barrier function, cell impedance was determined. CHO cells were 
grown on gold-plated microtiter wells, and monolayer integrity was 
FIGURE 2: N-glycosylation is not required for JAM-A transport but regulates homodimerization 
and stability. (A) CHO cells expressing wt or N185Q human JAM-A were incubated with 
sulfo-NHS-biotin to label surface-exposed proteins. Biotinylated proteins were precipitated 
using streptavidin–agarose and detected by Western blot analysis. The data are representative 
of three separate experiments. (B) CHO cells expressing wt, N185Q, or 6163 JAM-A and some 
cells were incubated with BS3 to cross-link proteins. Cells were processed for Western blot 
analysis. (C) CHO cells expressing wt or N185Q human JAM-A were incubated with 100 μM 
cycloheximide (CHX) for up to 24 h. Lysates were subjected to Western blot analysis for JAM-A 
and β-actin and densitometric analysis conducted using ImageJ. Statistical comparisons were 
assessed between the samples at each time point using a two-tailed Student’s t test. *p < 0.05 
between the samples from four separate experiments.
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JAM-A glycosylation patterns are cell-type specific
Having confirmed that JAM-A contains N-glycans that regulate the 
protein’s function, and in light of both our findings and previously 
published data demonstrating that JAM-A’s effects are cell-type 
specific, we investigated whether the glycoprotein’s saccharide 
content varied across a panel of endothelial and epithelial cells, as 
well as when the protein was exogenously expressed, using lectin 
affinity pull down (lectin specificity outline in Table 1). To test for 
sialic acid, a common capping sugar on N-glycan structures, we 
incubated human cells lines with Sambucus nigra lectin (SNA), a 
lectin that recognizes α-2,6-linked sialic acid, which is added to 
cells via the enzyme ST6GAL1. CHO cells express low levels of 
ST6GAL1 and were thus also tested with Maackia amurensis lectin 
(MAA), a lectin that recognizes α-2,3 sialic acid, the predominant 
sialic acid structure in these cells (Lee et al., 1989; Xu et al., 2011). 
As seen in Figure 7, N-glycans from all cell lines tested contained 
bianternary (LCA), trianternary (PHA-E), and sialyated structures 
(SNA or MAA). Of interest, UEA-1, a lectin specific for fucose, in-
teracted with JAM-A produced in epithelial but not endothelial 
cells or cell expressing exogenous JAM-A. These data demon-
strate a conserved N-glycan profile of JAM-A, including the global 
JAM-A N-glycosylation controls leukocyte binding
JAM-A supports leukocyte adhesion (Ostermann et al., 2002). Spe-
cifically, the second Ig-like domain, where N185 is located, interacts 
with LFA-1 (Fraemohs et al., 2004). As can be seen in Figure 6A, 
CHO cells expressing wt JAM-A supported significantly increased 
leukocyte adhesion compared with EV control cells. Strikingly, 
N185Q-expressing cells did not support leukocyte binding above 
EV control, suggesting that glycosylation of this residue is involved 
in LFA-1 binding.
To confirm this interaction, we tested the ability of CHO cells 
with or without JAM-A proteins to bind to LFA-1. CHO cells will not 
bind to LFA-1/fc chimeras unless they express JAM-A (Fraemohs 
et al., 2004). As can be seen in Figure 6, B and C, cells expressing wt 
JAM-A demonstrated significantly more adhesion to LFA-1/fc than 
did EV cells. In contrast, cells expressing N185Q failed to adhere at 
levels above EV, indicating that N-glycosylation of JAM-A is re-
quired for LFA-1 binding. To confirm the specificity of LFA-1 bind-
ing, we assessed CHO cells expressing EV, JAM-A, or ICAM-1 for 
their ability to bind LFA-1/fc–coated beads. Cells expressing JAM-A 
and ICAM-1 bound significantly more beads than EV control (Sup-
plemental Figure S7), confirming specificity of the ligand.
FIGURE 3: N-glycosylation regulates JAM-A–mediated increases in barrier integrity. (A) CHO cells expressing empty 
vector or wt or N185Q JAM-A were grown on 0.4-μm Transwell inserts for 48 h. FITC-dextran (10 kDa) was added to the 
upper chamber and measured from the lower chamber after 2 h of incubation. Data shown are representative of three 
separate experiments run in triplicate. Statistical differences were determined by one-way analysis of variance (ANOVA) 
with Tukey’s posttest. *p < 0.05 vs. empty vector and N185Q. (B) The same cells as in A were grown on RTCA plates, 
and impedance was assessed for 30 h. Data shown are representative of four separate experiments run in 
quadruplicate. Statistical differences were determined by two-way ANOVA with Bonferroni posttest against empty 
vector. (C) CHO cells transfected with empty vector or wt or N185Q human JAM-A were assayed for Rap1 activity by 
pull down using GST-RalGDS-RBD. (D) Quantification. *p < 0.05 vs. EV; ***p < 0.01 vs. EV; #p < 0.05 vs. wt by one-way 
ANOVA with Tukey’s posttest from four separate experiments.
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increases Rap1 activity. Dimerization of JAM-A is reported to occur 
through key residues in the first Ig-like domain (Ostermann et al., 
2002; Mandell et al., 2004). Atomic force microscopy experiments 
elegantly demonstrated, however, that these dimers are stabilized 
by the second Ig-like domain, the region where N185 is located 
(Wojcikiewicz et al., 2009), although it was unclear what portion of 
the second Ig-like domain was involved. We now identify N-glycans 
bound at N185 as regulators of dimerization. There are numerous 
reports of N-glycans regulating homodimers to control protein func-
tion, such as E-cadherin, platelet endothelial cell adhesion molecule 
1 (PECAM-1), and N-cadherin (Guo et al., 2009; Pinho et al., 2011; 
Langer et al., 2012). For example, expression of PECAM-1 is re-
duced in cells that are missing ST6GAL1, a gene responsible for the 
addition of α-2,6 sialic acid on N-glycans. Loss of this enzyme results 
in decreased PECAM-1 surface residency and a loss of antiapoptotic 
signaling associated with the protein (Kitazume et al., 2014). In ad-
dition, it has been reported that these sialic acid residues, which are 
similar to the ones on JAM-A, regulate dimerization of PECAM-1 
(Kitazume et al., 2010).
Several reports suggested that JAM-A controls cell motility and 
migration (Bazzoni et al., 2005; Naik et al., 2008; McSherry et al., 
2009; Gotte et al., 2010; Murakami et al., 2011; Cao et al., 2014). 
However, the results from these studies have been conflicting. For 
example, it was reported that JAM-A expression decreases migra-
tion of murine endothelial and MDA-MB-231 cells but increases the 
presence of sialic acid and epithelial cell–specific presence of 
fucose.
DISCUSSION
Before this study, the extent of N-glycosylation on JAM-A and its 
involvement in the protein’s functions were unknown. We have 
shown that human JAM-A carries a single N-glycan at residue N185 
but not on the previously implicated residue N191 (Figure 1). Glyco-
sylation of N185 is not required for surface transport but regulates 
dimerization and protein half-life (Figure 2). N-glycosylation of JAM-
A at N185 is also a critical regulator of barrier function (Figure 3) and 
cell migration (Figures 4 and 5). Our data also indicate that N-gly-
cans at N185 of JAM-A are required for leukocyte binding via LFA-1 
(Figure 6). Finally, we report cell-specific JAM-A N-glycan signatures 
(Figure 7). Taken together, these data indicate that N-glycosylation 
of JAM-A is critical for the protein’s function.
JAM-A is known to control barrier function in CHO cells (Martin-
Padura et al., 1998; Aurrand-Lions et al., 2001), as well as in some 
epithelial cells (Monteiro and Parkos, 2012; Monteiro et al., 2014). 
The reported mechanism is believed to be by controlling Rap1/2 
activity, which is also dependent on JAM-A homodimerization 
(Severson et al., 2008; Monteiro et al., 2014). In the present study, 
we also found that JAM-A is able to increase barrier function and 
increase Rap1 activity in CHO cells. The N-glycan deficient JAM-A 
N185Q mutant does not increase barrier function and only slightly 
FIGURE 4: N-glycosylation controls JAM-A–mediated cell motility. Cell spreading was assessed by determining total 
cell area (A) or measuring cell impedance using RTCA (B). The total number of cells used in A was as follows: EV, 47; wt, 
49; N185Q, 46. RTCA data are representative of three separate experiments run in quadruplicate. CHO cells expressing 
empty vector or wt or N185 JAM-A were plated on FN-coated glass-bottom dishes, and single-cell motility was 
assessed as velocity (C) and persistence (directionality/time) (D) using time-lapse images. The data are averages ± SEM 
from three different experiments. The total number of cells was as follows: EV, 52; wt, 53; N185Q, 46. Statistical 
differences were determined by one-way ANOVA with Tukey’s posttest. *p < 0.05 vs. EV and N185Q.
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One of the first reported functions of JAM-A was as a leukocyte 
receptor and regulator of diapedesis (Martin-Padura et al., 1998). In 
support of this, JAM-A−/− mice have been shown to have defects in 
leukocyte trafficking in disparate models of disease (Azari et al., 
2010; Lakshmi et al., 2012; Schmitt et al., 2014). JAM-A controls 
diapedesis by interacting with LFA-1 expressed on leukocytes 
(Fraemohs et al., 2004). It has been known for some time that this 
migration of murine neutrophils, HUVECs, and MCF7 cells (Bazzoni 
et al., 2005; Naik and Naik, 2006; Naik et al., 2008; Cera et al., 2009; 
McSherry et al., 2009). In Figure 4 and Supplemental Figure S3, we 
show that JAM-A regulates cell spreading of HUVECs and MDA-
MB-231 but not CHO cells. In addition, Figure 4 and Supplemental 
Figure S4 demonstrate that expression of exogenous wt JAM-A re-
duces random motility of all cells tested. One possible explanation 
for these cell type–specific effects could be unique N-glycan profiles 
associated with the different cells. Figure 7 demonstrates that cell-
specific N-glycan profiles of JAM-A do exist; if and how these spe-
cific modifications regulate protein function are worthy of additional 
investigation.
Changes in N-glycosylation are often associated with cellular 
transformation and inflammation and could influence JAM-A func-
tion (Couldrey and Green, 2000; Chacko et al., 2011; Guo et al., 
2012; Scott et al., 2012; Liu et al., 2013). It is intriguing to speculate 
that changes in JAM-A N-glycosylation as a result of disease pro-
gression could result in a loss-of-function state, such as is reported 
her earlier with the N185Q mutant. In fact, N185S is reported as a 
somatic mutation in breast cancer in the COSMIC database 
(Bamford et al., 2004). This mutation would likely result in a loss of 
JAM-A function and lead to a more aggressive cell phenotype, 
which has been described in breast cancer cells lacking JAM-A (Naik 
et al., 2008). Additional studies are needed to determine whether 
N185S behaves as a dominant negative when compared with the 
results obtained with wt JAM-A, which restored a normal breast epi-
thelial phenotype (Naik et al., 2008).
FIGURE 5: N-glycosylation controls JAM-A–mediated decrease in 
wound closure. CHO cells expressing EV or wt or N185Q JAM-A were 
grown to confluence on FN-coated glass-bottom dishes. A wound 
was made across the entire length of the glass insert using the tip of a 
200-μl pipette tip, and closure was assessed over a 24-h period. 
(A) Representative micrographs at the beginning (0 h) and end (24 h) 
of an experiment. (B) Quantitation of wound closure. Five separate 
regions from each dish were monitored for closure. Data presented 
are the average ± SEM of the five regions from one dish and are 
representative of four separate experiments. Statistical differences 
were determined by one-way ANOVA with Tukey’s posttest. *p < 0.05 
vs. EV; **p < 0.05 vs. EV and N185Q.
FIGURE 6: N-glycosylation of JAM-A is required for interactions with 
LFA-1. (A) Equal numbers of HL-60 cells were added to glass 
coverslips covered with confluent CHO cells expressing empty vector 
or wt or N185Q JAM-A in the presence of 100 μg/ml PMA for 30 min. 
Adherent HL-60 cells were counted after washing. Data are 
representative of three separate experiments run in triplicate. 
Statistical differences were determined by one-way ANOVA with 
Tukey’s posttest. *p < 0.05 vs. EV and N185Q. (B) CHO cells labeled 
with CellTracker Green and expressing empty vector or wt or N185Q 
human JAM-A were allowed to adhere to microtiter plates coated 
with LFA-1/fc chimera (20 μg/ml). After washing, adherent cells were 
assessed on a fluorometer. Data are representative of three separate 
experiments. *p < 0.05 vs. EV and N185Q. (C) CHO cells expressing 
empty vector or wt or N185Q JAM-A were allowed to adhere and 
spread on RTCA plates coated with LFA-1/fc chimera (20 μg/ml) for 
90 min. Data are representative of two independent experiments run 
in quadruplicate. Statistical differences were assessed by two-way 
ANOVA with Bonferroni posttest against EV and N185Q. *p < 0.05, 
**p < 0.01, and ***p < 0.001 vs. EV. ##p < 0.05 and ###p < 0.01 vs. 
N185Q.
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binding motif on the third Ig-like domain of ICAM-1, which can be 
abolished by site-directed mutagenesis or production of the protein 
under conditions in which N-glycan complexity is limited. (Diamond 
et al., 1991; Scott et al., 2013). Further, the CD18 integrin, which is 
shared by LFA-1 and Mac1, binds ICAM-1 in a glycosylation-depen-
dent manner (Sriramarao et al., 1993). N-glycosylation at a single 
residue of ICAM-1, N103, is required for the proper positioning of 
the binding domain that interacts with LFA-1 (Diamond et al., 1991).
This report has demonstrated that N-glycosylation of human 
JAM-A at N185 is required for the protein’s known functions. These 
findings identify a novel regulator of JAM-A function and one that is 
altered during disease. It will be interesting to determine whether 
changes in glycosylation of JAM-A could affect JAM-A function dur-
ing disease, leading to compromised barrier function and altered 
junctional stability. Future studies are needed to determine the N-
glycan composition of JAM-A and understand how this changes 
during inflammation and disease.
MATERIALS AND METHODS
Cell culture and transfections
CHO-K1, HL-60, MDA-MB-231, A549, Caco-2, and MCF7 cells 
were purchased from the American Type Culture Collection 
(Manassas, VA). CHO-K1 and MDA-MB-231 were propagated in 
high-glucose DMEM (Invitrogen, Carlsbad, CA) containing 10% fe-
tal bovine serum (FBS; Sigma-Aldrich, St. Louis, MO) and antibi-
otic/antimycotic solution (Invitrogen). MCF7 and HL-60 cells were 
propagated in RPMI-1640 containing 10% FBS and antibiotic/anti-
mycotic solution. Caco-2 cells were propagated in MEM contain-
ing 20% FBS and antibiotic/antimycotic solution. HUVECs and hu-
man pulmonary microvascular endothelial cells were purchased 
from Lonza and cultured in EGM-2 + bullet kit (Lonza, Walkersville, 
MD). Transfections were performed using Lipofectamine 2000 
(Invitrogen) according to the manufacturer’s recommendations. To 
generate stable lines, transfected cells were grown in the forego-
ing media supplemented with 1000 μg/ml G418 (Invitrogen) 
for 3 wk, at which time, individual colonies were selected and 
expanded. For knockdown of JAM-A, cells were transfected 
with SMARTpool ON-TARGET PLUS siRNA against human f11r 
(Dharmacon, Lafayette, CO) at a final concentration of 10 nM.
Plasmid and site-directed mutagenesis
The pCDNA3.1 HA-JAM-A plasmid was previously described (Naik 
et al., 2001) and generously provided by Ulhas Naik (University of 
Delaware, Newark, DE). The pCMV ICAM-1 plasmid was previously 
described (Scott et al., 2013). Site-directed mutagenesis to generate 
N185Q, N191Q, and 6163 was achieved by overlap PCR and con-
firmed by sequencing using the following primers. N185Q: forward, 
5′-cacccgtgccttcagccagtcttcctatgtcctga-3′, and reverse, 5′-tcagga-
cataggaagactggctgaaggcacgggtg-3′. N191Q: forward, 5′-aactcttcc-
tatgtcctgcagcccacaacaggagagctg-3′, and reverse, 5′-cagctctcctgtt-
gtgggctgcaggacataggaagagtt-3′. 6163: forward, 5′-gtctccttggtcaaa-
cgcccacgccacacggggagaaga-3′, and reverse, 5′-tcttctccccgtgtgg-
cgtgggcgtttgaccaaggagac-3′.
Rap1 activity assay
Rap1 activity was determined as previously described (Wittchen 
et al., 2005). Briefly, cells were lysed (50 mm Tris, pH 7.4, 75 mm 
NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, and 0.1% SDS 
containing protease inhibitors and 1 μM sodium vanadate) and 
clarified by centrifugation. Active Rap1 was captured by incubation 
with 50 μg of glutathione S-transferase (GST)–RalGDS-RBD immo-
bilized on glutathione–Sepharose beads. Active Rap1 bound to 
interaction involves the second Ig-like domain of JAM-A, but the 
precise region of binding was unknown. The present data suggest 
that the N-glycan at N185 is required for this function. At least two 
possible scenarios exist by which this N-glycan could control LFA-1 
binding. First, it is possible that this N-glycan residue is required for 
positioning the amino acids within JAM-A that serve as a ligand for 
LFA-1. The second possibility is that the N-glycans themselves di-
rectly interact with LFA-1 or with an associated molecule on the sur-
face of the leukocyte that controls LFA-1 to mediate the interaction. 
As examples, N-glycans of intercellular adhesion molecule 1 (ICAM-
1) regulate the binding of both LFA-1 and MAC-1. In the case of 
MAC-1, complex N-glycans at positions N240 and N269 block the 
FIGURE 7: JAM-A N-glycan content differs between epithelial and 
endothelial cells. Endogenous expression of JAM-A from MCF7, 
A549, Caco-2, HUVEC, and pulmonary microvascular endothelial cells 
(HPmvEC) (A) and exogenous expression of the protein in CHO and 
MDA-MB-231 (B) was analyzed for N-glycan content after lysis and 
incubation with agarose-bound lectins as described in the Materials 
and Methods. Bound proteins were subjected to Western blot 
analysis for detection of JAM-A. Data are representative of two to 
four experiments per cell type.
Lectin Specificity
Lens culinaris agglutinin (LCA) Biantennary N-glycan
Phaseolus vulgaris erythroagglutinin 
(PHA-E)
Triantennary N-glycan
P. vulgaris leucoagglutinin (PHA-L) Tetraantennary N-glycan
Ulex europaeus agglutinin I (UEA-1) α-Linked fucose
S. nigra lectin (SNA) α-2,6-Linked sialic acid
M. amurensis lectin II (MAA) α-2,3-Linked sialic acid
TABLE 1: Lectin specificity.
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a 30-μm filter (04-004-2326; Partec). Cell populations were profiled 
for Alexa Fluor 488 signal with 488/525 ± 20 nm (excitation/emis-
sion) settings on a Bio-Rad S3 cell sorter. Cytometry data were ana-
lyzed with FlowJo software.
Haptotaxis assay
The bottoms of 8-μm-pore Transwell inserts (Corning, Corning, 
NY) were coated with FN (20 μg/ml) or vitronectin (20 μg/ml; 
Advanced Biomatrix, San Diego, CA). Cells were serum starved 
for 2 h before being added to the wells and given 4 h to migrate. 
Cells were fixed in ice-cold ethanol, cells from the upper cham-
ber were gently removed with a cotton swab, and the migrated 
cells on the lower chamber were stained with Alexa 488–conju-
gated phalloidin. Three fields of view from three Transwells per 
condition were captured and averaged per experiment.
Immunostaining
Cells plated onto glass coverslips were fixed with ice-cold methanol 
before being blocked with 5% BSA in PBS. Cells were stained with 
antibody against JAM-A (sc-53624; Santa Cruz Biotechnology) and 
counterstained with Alexa Fluor 488–conjugated secondary and 
Hoechst 33342 (Invitrogen). Samples were mounted with Fluoro-Gel 
(17985-11; Electron Microscopy Sciences, Hatfield, PA) and imaged 
on an Olympus FV1000 confocal microscope using a 40× (numerical 
aperture 1.3) objective with 1.7× digital magnification. Image chan-
nels were pseudocolored and merged using ImageJ.
Single-cell tracking of motility
Cells were plated onto FN-coated (25 μg/ml) glass-bottom cul-
ture dishes 4–6 h before imaging. Time-lapse microscopy was 
performed on an incubator-housed microscope (20× objective; 
VivaView FL) with a camera (Orca ER/AG type c4742-80-12AG) 
with image acquisition every 15 min for 12 h. Cell velocity and 
persistence were measured with ImageJ using the Manual Track-
ing plug-in.
Monocyte adhesion assay
CHO cells were grown on FN-coated (10 μg/ml) 12-mm glass cov-
erslips in 24-well plates and switched to serum-free medium 2 h 
before the experiment. Just before the experiment, the CHO cells 
were washed and then incubated in Hanks balanced salt solution 
(HBSS) containing CellTracker Green (Life Technologies)–labeled 
HL-60 cells (1.5 × 106 cells/dish) in the presence of 100 ng/ml 
phorbol myristate acetate (PMA) for 30 min. Cells were gently 
washed in warm PBS containing CaCl2 and MgCl2 to remove any 
unbound cells before being fixed with 3.7% formaldehyde in the 
same buffer for 20 min. Five random fields of view from three sep-
arate coverslips per condition were analyzed and quantified as 
cells per field of view. Images were captured using a Zeiss Axiovert 
200M microscope equipped with a 20× objective lens and a Ham-
amatsu ORCA-ERAG digital camera. The experiment was con-
ducted three times, and representative results from one experi-
ment are shown.
CHO cell adhesion to fc-chimeric proteins
Black-walled 96-well microtiter (Corning) or E-16 RTCA plates were 
coated with LFA-1/fc chimera (20 μg/ml; R&D Biosystems) or JAM-
A/fc (20 μg/ml) in 10 mM Tris, pH 9.0, at 4°C overnight. For some 
experiments JAM-A/fc was digested with 0.1 U of PNGaseF (Sigma- 
Aldrich) for 1 h at 37°C to remove N-glycans. Wells were then 
blocked with 0.5% heat- denatured BSA in PBS for 1 h at room tem-
perature. CHO cells were labeled with CellTracker Green (and 
beads was compared with total levels (from reserved input) by 
Western blot.
Western blot analysis
Lysates were resolved on SDS–PAGE gels and proteins transferred 
to nitrocellulose membranes. Blots were blocked with 3% bovine 
serum albumin (BSA) in Tris-buffered saline containing Tween-20 
(TBST; 25 mM Tris, pH 7.6, 150 mM NaCl, 0.2% Tween-20). Blots 
were probed with primary antibodies against JAM-A (612120; BD 
Biosciences, San Jose, CA), Rap1 (2399; Cell Signaling, Danvers, 
MA), CD29 (9699, for human cell lines; Cell Signaling), CD29 
(MAB2405, CHO cells; R&D Biosystems, Minneapolis, MN), 
ICAM-1 (4915; Cell Signaling), and β-actin (14-1116; Millipore, 
Billerica, MA). After washing with TBST, blots were incubated with 
species-appropriate horseradish peroxidase–conjugated second-
ary antibodies (Jackson Laboratories, West Grove, PA), and signals 
were detected using enhanced chemiluminescence substrate with 
x-ray film or a Bio-Rad Chemidoc system. Densitometric analysis 
was conducted on scanned films using ImageJ (National Institutes 
of Health, Bethesda, MD).
RTCA and cell spreading
Before plating, cells were incubated in DMEM containing 0.5% 
delipidated BSA and antibiotic-antimycotic solution for 1 h. Cells 
were then resuspended in the same medium for 1 h with gentle 
rotation. For the RTCA xCELLigence System (Roche Applied 
Sciences), 2000 cells/well were added to an E-plate 16 coated 
with fibronectin (FN; 25 μg/ml). Attachment and spreading were 
monitored as cell index, an arbitrary unit of cell impedance. For 
analysis of total spread area, cells were prepared as described and 
added to glass coverslips coated with 25 μg/ml FN. Cells were 
fixed with ice-cold ethanol and stained with Alexa 488–phalloidin 
(Invitrogen). Micrographs were captured using a Zeiss Axiovert 
200M microscope equipped with a 63× objective lens and a 
Hamamatsu ORCA-ERAG digital camera. Area was calculated us-
ing ImageJ.
Wound-healing assay
Cells were plated onto FN-coated (25 μg/ml) glass-bottom dishes at 
a confluent density. After a 24-h incubation, a wound was created 
using a 200-μl pipette tip. Images were acquired at 0, 4, 8, 12, and 
24 h after wounding. Each cell type was tested three times, with five 
regions per wound assessed. Percentage wound closure was calcu-
lated using ImageJ.
Lectin affinity pull down
Cells were lysed (50 mM Tris, 150 mM NaCl, 1% SDS, 5 μM 
2-mercaptoethanol) and boiled for 10 min. Lysates were diluted 
1:20 in TBS and incubated with 50 μl of lectin-conjugated aga-
rose (Vector Laboratories, Burlingame, CA) for 4 h at room tem-
perature. For MAA pull downs, 50 μg of biotin-tagged MAA (Vec-
tor Laboratories) was incubated with 50 μl of streptavidin agarose 
for 1 h at room temperature before addition of the lysates. Beads 
were washed five times with TBS, and bound proteins were re-
leased by boiling in sample buffer and processed for Western 
blot analysis as described.
Flow cyotometric analysis
Cells were trypsinized and incubated with Alexa Fluor 488–conju-
gated anti–JAM-A (FAB1103G; R&D Biosystems). Cells were washed 
three times in PBS, resuspended in sorting medium (2% FBS in PBS) 
containing 10 μg/ml DNase I and 5 mM EDTA, and passed through 
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allowed to adhere for 30 min at 37°C in HBSS. Wells were gently 
washed with warm PBS with 1 mM CaCl2 and MgCl2, and fluores-
cence of input and adherent cells was determined with a fluores-
cence plate reader (Tecan). Background binding to BSA-coated 
wells was negligible and subtracted.
Bead adhesion assay
Assays were performed as previously described (Lessey-Morillon 
et al., 2014). Briefly, 4.5-μm tosylactivated paramagnetic beads 
(Invitrogen) were coated with LFA-1/fc according to the manufac-
turer. Beads were added to confluent cells in a 1:1 ratio and allowed 
to adhere for 15 min. Cells were washed five times with warm PBS to 
remove any unattached beads. Five fields of view from two separate 
experiments were acquired, and bound beads were determined.
Surface biotinylation assay
CHO cells were grown to confluence and washed three times with 
warm PBS containing 1 mM CaCl2 and 1 mM MgCl2 before being 
incubated with the same buffer containing 0.5 mM sulfo-NHSbiotin 
(Pierce). After a 15-min incubation at room temperature, the reac-
tion was quenched by the addition of 25 mM glycine for 10 min. 
Cells were again washed with PBS and lysed (25 mM Tris, pH 7.6, 
150 mM NaCl, 0.1% SDS, 0.5% NP-40, protease inhibitors). Biotin-
tagged proteins were enriched on streptavidin agarose for 1 h and 
released by boiling in sample buffer. Precipitated proteins and re-
served input were analyzed for JAM-A by Western blot analysis.
BS3 cross-linking: detection of JAM-A dimerization
Cells were washed three times with ice-cold PBS containing CaCl2 
and MgCl2 (1 mM each) before being incubated with 5 μM BS3 
(Pierce) for 30 min at 4°C. The reaction was quenched by the addi-
tion of 25 μM glycine for 10 min at room temperature. Cells were 
washed three times and lysed directly in sample buffer for Western 
blot analysis.
Barrier function analysis
For FITC-dextran flux, cells were seeded (5 × 104 cells/well) onto 
FN-coated (10 μg/ml) 0.4-μm polycarbonate Transwell membranes 
(Corning) and cultured for 48 h. FITC-dextran (10 kDa) (Sigma-
Aldrich) at a final concentration of 1 mg/ml was added to the upper 
chamber, and after 2 h, medium from the bottom chamber was col-
lected and transferred to a black-walled, 96-well microtiter plate 
(Corning) for analysis. Fluorescence intensity was analyzed using a 
plate reader (Tecan; excitation 485 nm, emission 520 nm). For RTCA 
experiments, 5 × 104 cells were plated in each well of an E-Plate 16 
(Roche Applied Science), and cell index was assessed for 30 h.
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